Skip to main content
. Author manuscript; available in PMC: 2015 Jul 10.
Published in final edited form as: Nature. 2015 Apr 29;523(7559):221–225. doi: 10.1038/nature14452

Extended Data Figure 4. Constructs and validation of iFate mice.

Extended Data Figure 4

a, Targeting strategy and constructs of IL-17AeGFP-CRE-ERT2 mice (iFate). Black circles represent Flp recombinase target (FRT) sites. b, Schematic of TH17 cell development in iFate showing that TH17 cell plasticity can be tested only after tamoxifen treatment. c, iFate mice were injected with tamoxifen and anti-CD3 monoclonal antibody and non TH17 cells (IL-17AGFP−YFP−), TH17 YFP+ cells (IL-17AeGFP+ YFP−), TH17 cells (IL-17AeGFP+ YFP+) and exTH17 cells (IL-17AeGFP− YFP+) were FACS sorted. Il17a mRNA expression in the indicated populations is reported. The mRNA expression is normalized to HPRT. One representative experiment out of two is shown. d, Representative flow cytometric analysis of intestinal TH17 cells under steady state condition or after anti-CD3 monoclonal antibody (aCD3) in the absence of tamoxifen treatment. The efficiency of CRE-mediated recombination after tamoxifen is reported as frequencies of YFP+ cells (YFP) and is the result of the following calculation: YFP+ cells (gate 2 + 3)/(IL-17AeGFP+ YFP− cells (gate 1) + YFP+ cells (gate 2 + 3).